#United States #Brookfield #GTCR #Vernon Hills #Antylia

GTCR Completes Antylia Scientific Transaction

GTCR, a leading private equity firm based in Chicago, has recently announced the successful sale of Antylia Scientific for approximately $1.34 billion to Brookfield Asset Management and CDPQ. This strategic move signifies the culmination of a decade-long partnership that profoundly transformed Antylia's business landscape.

Overview of Antylia Scientific

Headquartered in Vernon Hills, Illinois, Antylia Scientific is a diversified life sciences company engaged in various sectors, including biopharmaceuticals, clinical diagnostics, and environmental testing. The company plays a crucial role in enhancing the precision of processes utilized in research and clinical laboratories. By providing essential products and services, Antylia supports thousands of long-term clients in maintaining the accuracy and repeatability required in their operations.

GTCR's partnership with Antylia began in 2014, following the acquisition of Cole-Parmer Instrument Company from Thermo Fisher Scientific. Under the guidance of Bernd Brust, the chairman of Antylia, and Jonathan Salkin, the company’s CEO, GTCR has successfully executed a robust growth strategy. Throughout this period, GTCR's investment funds contributed significantly to expanding Antylia’s geographic reach and diversifying its line of lab products. Notably, since the initial acquisition, Antylia has undertaken 15 add-on acquisitions that have further bolstered its portfolio in the life sciences sector.

Transformational Growth

The partnership between GTCR and the Antylia team is highlighted by the company’s evolution into a prominent player within the life sciences industry. Sean Cunningham, Managing Director of GTCR, expressed pride in the transformation that Bernd, Jon, and their entire team accomplished, noting that the business grew from a fledgling idea to a robust enterprise that exemplified GTCR's Leaders Strategy™ approach.

Among the key milestones during this partnership was the divestiture of Antylia's Masterflex bioprocessing business segment to Avantor Inc. in a strategic move that valued the unit at an impressive $2.9 billion. This transaction underscored the success of diversifying Antylia's operations and focusing on high-growth bioprocessing assets that support biologic drug and vaccine production.

Future Outlook

Following the sale, the leadership at GTCR looks forward to witnessing the continued innovation and growth of Antylia within the life sciences arena. The partnership is seen as a pivotal example of how strategic investments and collaborative relationships can fuel substantial business achievements and sector advancements. Jonathan Salkin, CEO of Antylia, acknowledged the invaluable support from GTCR, attributing Antylia's success to this fruitful collaboration.

As GTCR moves forward, the firm will likely continue identifying emerging opportunities across various sectors, especially in transformative growth in healthcare and technology-based businesses, while Antylia aims to maintain its momentum in driving innovation across its extensive portfolio. This sale marks a significant transition for both entities, promising a future filled with potential and further successes.

Conclusion

In summary, the sale of Antylia Scientific by GTCR reflects a successful strategic partnership that has redefined the life sciences business landscape over the last decade. With Antylia poised for its next chapter under new ownership, all eyes will be on its journey as it continues to develop and expand its impactful role in the industry.